Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,640.00
-30.00 (-0.39%)
Apr 29, 2026, 3:30 PM KST
-30.48%
Market Cap 178.38B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 23.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 107,471
Average Volume 99,482
Open 7,670.00
Previous Close 7,670.00
Day's Range 7,560.00 - 7,700.00
52-Week Range 7,340.00 - 11,560.00
Beta 0.90
RSI 41.49
Earnings Date Nov 11, 2025

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements

News

There is no news available yet.